Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04411680 · ClinicalTrials.gov registry record · Phase 2
Study of Sargramostim in Patients With COVID-19
A Phase 2 study, sponsored by Partner Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT04411680 is a Phase 2 study that has completed, run by Partner Therapeutics. The registered enrollment target is 123 participants.
The verdict
NCT04411680, a Phase 2 study, has completed, sponsored by Partner Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
The purpose of this research is to find out if a drug (sargramostim) also known as Leukine® could help patient recover faster from COVID-19. Sargramostim may help the lungs recover from the effects of COVID-19, and this research study will help to find this out.
Interventions
- DRUG Sargramostim
- DRUG Standard of care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2021-05-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04411680
The ClinicalTrials.gov registry entry for NCT04411680 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Partner Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sargramostim is the first listed.
NCT04411680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04411680 about?
NCT04411680 is a clinical study titled "Study of Sargramostim in Patients With COVID-19". The purpose of this research is to find out if a drug (sargramostim) also known as Leukine® could help patient recover faster from COVID-19. Sargramostim may help the lungs recover from the effects of COVID-19, and this research study will help to find this out.
What is the current status of trial NCT04411680?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2020-08-18. Estimated completion is 2021-05-19.
What interventions are being tested in trial NCT04411680?
The interventions under investigation include: Sargramostim (DRUG), Standard of care (DRUG).
Who is sponsoring clinical trial NCT04411680?
This trial is sponsored by Partner Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.